Cancer Screening
Recently Published Documents


TOTAL DOCUMENTS

25623
(FIVE YEARS 11894)

H-INDEX

174
(FIVE YEARS 61)

2021 ◽  
Vol 4 (12) ◽  
pp. e2136798
Author(s):  
A. Mark Fendrick ◽  
Nicole Princic ◽  
Lesley-Ann Miller-Wilson ◽  
Kathleen Wilson ◽  
Paul Limburg

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Kosmas V. Kepesidis ◽  
Masa Bozic-Iven ◽  
Marinus Huber ◽  
Nashwa Abdel-Aziz ◽  
Sharif Kullab ◽  
...  

Abstract Background Breast cancer screening is currently predominantly based on mammography, tainted with the occurrence of both false positivity and false negativity, urging for innovative strategies, as effective detection of early-stage breast cancer bears the potential to reduce mortality. Here we report the results of a prospective pilot study on breast cancer detection using blood plasma analyzed by Fourier-transform infrared (FTIR) spectroscopy – a rapid, cost-effective technique with minimal sample volume requirements and potential to aid biomedical diagnostics. FTIR has the capacity to probe health phenotypes via the investigation of the full repertoire of molecular species within a sample at once, within a single measurement in a high-throughput manner. In this study, we take advantage of cross-molecular fingerprinting to probe for breast cancer detection. Methods We compare two groups: 26 patients diagnosed with breast cancer to a same-sized group of age-matched healthy, asymptomatic female participants. Training with support-vector machines (SVM), we derive classification models that we test in a repeated 10-fold cross-validation over 10 times. In addition, we investigate spectral information responsible for BC identification using statistical significance testing. Results Our models to detect breast cancer achieve an average overall performance of 0.79 in terms of area under the curve (AUC) of the receiver operating characteristic (ROC). In addition, we uncover a relationship between the effect size of the measured infrared fingerprints and the tumor progression. Conclusion This pilot study provides the foundation for further extending and evaluating blood-based infrared probing approach as a possible cross-molecular fingerprinting modality to tackle breast cancer detection and thus possibly contribute to the future of cancer screening.


Vaccine ◽  
2021 ◽  
Author(s):  
Charlotte Wirtz ◽  
Yasmin Mohamed ◽  
Danielle Engel ◽  
Anissa Sidibe ◽  
Megan Holloway ◽  
...  

2021 ◽  
Vol 204 (11) ◽  
pp. P19-P20
Author(s):  
Yaron B Gesthalter ◽  
Eric J Seeley

2021 ◽  
pp. 096914132110596
Author(s):  
David Carr ◽  
David Kent ◽  
H. Gilbert Welch

A randomized trial of the GRAIL GalleriTM multi-cancer screening test is being planned for the National Health Service in England, and will have 140,000 healthy participants aged 50–79: 70,000 exposed to screening and 70,000 unexposed. The test reportedly detects 50 different cancers and is expected to reduce all-cancer mortality by approximately 25%. Given this effect size—and that cancer deaths constitute a large fraction of all deaths—the trial is sufficiently large to test the effect on all-cause mortality. Because most patients believe cancer screening “saves lives”, the GRAIL/National Health Service collaboration could set the evaluation standard for multi-cancer screening.


Sign in / Sign up

Export Citation Format

Share Document